465 related articles for article (PubMed ID: 32578967)
21. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
22. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
[TBL] [Abstract][Full Text] [Related]
23. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
24. Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction.
Selvaraj S; Ilkhanoff L; Burke MA; Freed BH; Lang RM; Martinez EE; Shah SJ
J Am Soc Echocardiogr; 2014 Jan; 27(1):74-82.e2. PubMed ID: 24075945
[TBL] [Abstract][Full Text] [Related]
25. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA.
Almahmoud MF; Soliman EZ; Bertoni AG; Kestenbaum B; Katz R; Lima JAC; Ouyang P; Miller PE; Michos ED; Herrington DM
J Am Heart Assoc; 2018 Sep; 7(18):e008334. PubMed ID: 30371180
[TBL] [Abstract][Full Text] [Related]
26. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock SJ; Ferreira JP; Packer M; Zannad F; Filippatos G; Kondo T; McMurray JJV; Solomon SD; Januzzi JL; Iwata T; Salsali A; Butler J; Anker SD
Eur J Heart Fail; 2022 Oct; 24(10):1869-1878. PubMed ID: 35796209
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of sST2 in patients with heart failure with reduced, mid-range and preserved ejection fraction.
Song Y; Li F; Xu Y; Liu Y; Wang Y; Han X; Fan Y; Cao J; Luo J; Sun A; Hu K; Zhou J; Ge J
Int J Cardiol; 2020 Apr; 304():95-100. PubMed ID: 32019693
[TBL] [Abstract][Full Text] [Related]
28. Modified Glasgow Prognostic Score is a novel predictor of clinical outcome in heart failure with preserved ejection fraction.
Bolat I; Biteker M
Scand Cardiovasc J; 2020 Jun; 54(3):174-178. PubMed ID: 31965867
[No Abstract] [Full Text] [Related]
29. New echocardiographic predictors of clinical outcome in patients presenting with heart failure and a preserved left ventricular ejection fraction: a subanalysis of the Ka (Karolinska) Ren (Rennes) Study.
Donal E; Lund LH; Oger E; Hage C; Persson H; Reynaud A; Ennezat PV; Bauer F; Drouet E; Linde C; Daubert C;
Eur J Heart Fail; 2015 Jul; 17(7):680-8. PubMed ID: 26033771
[TBL] [Abstract][Full Text] [Related]
30. The prognostic value of highly sensitive cardiac troponin assays for adverse events in men and women with stable heart failure and a preserved vs. reduced ejection fraction.
Gohar A; Chong JPC; Liew OW; den Ruijter H; de Kleijn DPV; Sim D; Yeo DPS; Ong HY; Jaufeerally F; Leong GKT; Ling LH; Lam CSP; Richards AM
Eur J Heart Fail; 2017 Dec; 19(12):1638-1647. PubMed ID: 28849609
[TBL] [Abstract][Full Text] [Related]
31. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
32. Prevalence and Prognostic Significance of Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.
Arnold JR; Kanagala P; Budgeon CA; Jerosch-Herold M; Gulsin GS; Singh A; Khan JN; Chan DCS; Squire IB; Ng LL; McCann GP
JACC Cardiovasc Imaging; 2022 Jun; 15(6):1001-1011. PubMed ID: 35033490
[TBL] [Abstract][Full Text] [Related]
33. Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: a pooled analysis of 12 cohort studies.
Zhang X; Yang S; Hao S; Li J; Qiu M; Chen H; Huang Y
Eur Radiol; 2024 Mar; 34(3):1854-1862. PubMed ID: 37658896
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction.
Yin D; Yan X; Bai X; Tian A; Gao Y; Li J
ESC Heart Fail; 2023 Apr; 10(2):1025-1034. PubMed ID: 36519216
[TBL] [Abstract][Full Text] [Related]
35. Secreted Frizzled-Related Protein 2 and Extracellular Volume Fraction in Patients with Heart Failure.
Yang S; Chen H; Tan K; Cai F; Du Y; Lv W; Hu Q; Hu Y; Huang Y
Oxid Med Cell Longev; 2020; 2020():2563508. PubMed ID: 32454934
[TBL] [Abstract][Full Text] [Related]
36. Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome.
Schelbert EB; Fridman Y; Wong TC; Abu Daya H; Piehler KM; Kadakkal A; Miller CA; Ugander M; Maanja M; Kellman P; Shah DJ; Abebe KZ; Simon MA; Quarta G; Senni M; Butler J; Diez J; Redfield MM; Gheorghiade M
JAMA Cardiol; 2017 Sep; 2(9):995-1006. PubMed ID: 28768311
[TBL] [Abstract][Full Text] [Related]
37. Extracellular Volume Fraction for Characterization of Patients With Heart Failure and Preserved Ejection Fraction.
Rommel KP; von Roeder M; Latuscynski K; Oberueck C; Blazek S; Fengler K; Besler C; Sandri M; Lücke C; Gutberlet M; Linke A; Schuler G; Lurz P
J Am Coll Cardiol; 2016 Apr; 67(15):1815-1825. PubMed ID: 27081022
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast-growth-factor-23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes.
Kanagala P; Arnold JR; Khan JN; Singh A; Gulsin GS; Eltayeb M; Gupta P; Squire IB; McCann GP; Ng LL
ESC Heart Fail; 2020 Dec; 7(6):4089-4099. PubMed ID: 32935918
[TBL] [Abstract][Full Text] [Related]
39. Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction.
Vergaro G; Del Franco A; Aimo A; Gentile F; Castiglione V; Saponaro F; Masotti S; Prontera C; Fusari N; Emdin M; Passino C
BMC Cardiovasc Disord; 2023 Sep; 23(1):433. PubMed ID: 37658340
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of N-terminal pro C-type natriuretic peptide in heart failure patients with preserved and reduced ejection fraction.
Lok DJ; Klip IT; Voors AA; Lok SI; Bruggink-André de la Porte PW; Hillege HL; Jaarsma T; van Veldhuisen DJ; van der Meer P
Eur J Heart Fail; 2014 Sep; 16(9):958-66. PubMed ID: 25082741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
